FDA Lays Out Endpoints, Monitoring Requirements for cUTI Trials

Drug Industry Daily
A A
FDA is doubling the monitoring period for subjects in trials for antibiotics to treat complicated urinary tract infections.

To View This Article:

Login

Subscribe To Drug Industry Daily